Allo HSCT Using RIC for Hematological Diseases
Public ClinicalTrials.gov record NCT02661035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]
Study identification
- NCT ID
- NCT02661035
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Enrollment
- 156 participants
Conditions and interventions
Conditions
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- B-Cell Lymphoma
- Burkitt's Lymphoma
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Follicular Lymphoma
- Hematological Diseases
- Lymphoblastic Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle-Cell Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Syndromes
- Non-Hodgkin's Lymphoma
- Plasma Cell Leukemia
- Prolymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- ATG Drug
- Allopurinol Drug
- Cyclophosphamide Drug
- Fludarabine Drug
- MMF Drug
- Peripheral Blood Stem Cells Biological
- Related or Unrelated Bone Marrow Cells Biological
- TBI Radiation
- Tacrolimus Drug
Drug · Biological · Radiation
Eligibility (public fields only)
- Age range
- Up to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2017
- Primary completion
- Apr 16, 2023
- Completion
- May 28, 2023
- Last update posted
- Sep 20, 2023
2017 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02661035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 20, 2023 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02661035 live on ClinicalTrials.gov.